Literature DB >> 19789239

RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment.

Fabian Kiessling1, Jochen Huppert, Chunfu Zhang, Jabadurai Jayapaul, Stefan Zwick, Eva C Woenne, Margareta M Mueller, Hanswalter Zentgraf, Michael Eisenhut, Yoseph Addadi, Michal Neeman, Wolfhard Semmler.   

Abstract

PURPOSE: To investigate the biologic effect of arginine-glycine-aspartic acid (RGD)-labeled ultrasmall superparamagnetic iron oxide (USPIO) (referred to as RGD-USPIO) on human umbilical vein endothelial cells (HUVECs), ovarian carcinoma (MLS) cells, and glioblastoma (U87MG) cells and on U87MG xenografts in vivo.
MATERIALS AND METHODS: All experiments were approved by the governmental review committee on animal care.USPIOs were coated with integrin-specific (RGD) or unspecific (arginine-alanine-aspartic acid [RAD]) peptides. USPIO uptake in HUVECs, MLS cells, and U87MG cells and in U87MG tumor xenografts was determined with T2 magnetic resonance (MR) relaxometry in 16 nude mice. Cells and tumors were characterized by using immunofluorescence microscopy. Trypan blue staining and lactate dehydrogenase assay were used to assess cytotoxicity. Statistical evaluation was performed by using a Mann-Whitney test or a linear mixed model with random intercept for the comparison of data from different experiments. Post hoc pairwise comparisons were adjusted according to a Tukey test.
RESULTS: HUVECs and MLS cells internalized RGD-USPIOs significantly more than unspecific probes. Controversially, U87MG cells accumulated RGD-USPIOs to a lesser extent than USPIO. Furthermore, only in U87MG cells, free RGD and alpha(v)beta(3) integrin-blocking antibodies strongly reduced endocytosis of nonspecific USPIOs. This was accompanied by a loss of cadherin-dependent intercellular contacts, which could not be attributed to cell damage. In U87MG tumors, RGD-USPIO accumulated exclusively at the neovasculature but not within tumor cells. The vascular accumulation of RGD-USPIO caused significantly higher changes of the R2 relaxation rate of tumors than observed for USPIO.
CONCLUSION: In glioma cells with unstable intercellular contacts, inhibition of alpha(v)beta(3) integrins by antibodies and RGD and RGD-USPIO disintegrated intercellular contacts and reduced endocytotic activity, illustrating the risk of inducing biologic effects by using molecular MR probes. (c) RSNA, 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789239     DOI: 10.1148/radiol.2532081815

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  23 in total

Review 1.  Implicit and explicit prior information in near-infrared spectral imaging: accuracy, quantification and diagnostic value.

Authors:  Brian W Pogue; Scott C Davis; Frederic Leblond; Michael A Mastanduno; Hamid Dehghani; Keith D Paulsen
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

2.  Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).

Authors:  Zhihao Zha; Seok Rye Choi; Karl Ploessl; Brian P Lieberman; Wenchao Qu; Franz Hefti; Mark Mintun; Daniel Skovronsky; Hank F Kung
Journal:  J Med Chem       Date:  2011-11-09       Impact factor: 7.446

3.  Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Authors:  Pubudu M Peiris; Aaron Abramowski; James Mcginnity; Elizabeth Doolittle; Randall Toy; Ramamurthy Gopalakrishnan; Shruti Shah; Lisa Bauer; Ketan B Ghaghada; Christopher Hoimes; Susann M Brady-Kalnay; James P Basilion; Mark A Griswold; Efstathios Karathanasis
Journal:  Cancer Res       Date:  2015-01-27       Impact factor: 12.701

4.  Combined non-invasive assessment of endothelial shear stress and molecular imaging of inflammation for the prediction of inflamed plaque in hyperlipidaemic rabbit aortas.

Authors:  Gitsios Gitsioudis; Yiannis S Chatzizisis; Peter Wolf; Anna Missiou; Antonios P Antoniadis; Dimitrios Mitsouras; Sönke Bartling; Zeynep Arica; Matthias Stuber; Frank J Rybicki; Max Nunninger; Christian Erbel; Peter Libby; George D Giannoglou; Hugo A Katus; Grigorios Korosoglou
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2016-03-24       Impact factor: 6.875

Review 5.  Targeted nanotechnology for cancer imaging.

Authors:  Randall Toy; Lisa Bauer; Christopher Hoimes; Ketan B Ghaghada; Efstathios Karathanasis
Journal:  Adv Drug Deliv Rev       Date:  2014-08-09       Impact factor: 15.470

Review 6.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

7.  ELTD1, a potential new biomarker for gliomas.

Authors:  Rheal A Towner; Randy L Jensen; Howard Colman; Brian Vaillant; Nataliya Smith; Rebba Casteel; Debra Saunders; David L Gillespie; Robert Silasi-Mansat; Florea Lupu; Cory B Giles; Jonathan D Wren
Journal:  Neurosurgery       Date:  2013-01       Impact factor: 4.654

8.  Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells.

Authors:  Xinying Wu; Yanbin Tan; Hui Mao; Minming Zhang
Journal:  Int J Nanomedicine       Date:  2010-08-09

Review 9.  Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis.

Authors:  Gustav J Strijkers; Ewelina Kluza; Geralda A F Van Tilborg; Daisy W J van der Schaft; Arjan W Griffioen; Willem J M Mulder; Klaas Nicolay
Journal:  Angiogenesis       Date:  2010-06       Impact factor: 9.596

10.  Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles.

Authors:  Fan Zhang; Xinglu Huang; Lei Zhu; Ning Guo; Gang Niu; Magdalena Swierczewska; Seulki Lee; Hong Xu; Andrew Y Wang; Khalid A Mohamedali; Michael G Rosenblum; Guangming Lu; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2012-05-03       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.